Loading...

SUPN SUPERNUS PHARMACEUTICALS INC Legal Disputes 8-K Filing

SPRN

SPN

SUPERNUS PHARMACEUTICALS INC

(SUPN)

2025 8-K

Executive Compensation Changes

Financial Results Reported

Quarterly Earnings Update

Merger Agreement Update

Q3 Results Update

Earnings Release Notice

Merger Completion

Financial Statements

Merger of Equals

Financial Statements

Regulatory Compliance

Financial Statements

Earnings Releases

Financial Results

Executive Compensation

Earnings Announcement

Q3 Earnings Report

Clinical Study Results

Earnings Announcement

Clinical Study Update

Webcast Announcement

FDA Resubmission

Earnings Reports

Annual Meeting of Stockholders

Interim Data Announcement

Earnings Reports

Compensation Modifications

Financial Results Announcement

Departure of Directors

Earnings Reports

Patent Infringement Ruling

Financial Results for Q3 2023

FDA Acknowledgment of Resub...

Research and Development Day

Resubmission of New Drug Ap...

Appointment of Director

Earnings Guidance

Settlement of Patent Litiga...

Annual Meeting Results

Financial Results Press Rel...

Earnings Reports

Compensation Modifications

Earnings Reports

Credit Line Agreement

External Links:

On May 22 and 23, 2025, Supernus Pharmaceuticals received Paragraph IV Notice Letters regarding Abbreviated New Drug Applications for viloxazine hydrochloride capsules and plans to protect its Qelbree® intellectual property. The company has six patents for Qelbree, with expiration dates between September 2029 and April 2035.

AI Assistant

SUPERNUS PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.